MDG1.DE Medigene AG (XETRA) -27% pre-market 16 Jan 2026: Oversold bounce watch
MDG1.DE stock plunged in pre-market trade on 16 Jan 2026, trading at €0.1335 after a -27.64% intraday move. The sharp drop came with volume at 189,470 shares, well above the 50-day average. For short-term traders using an oversold-bounce strategy, the gap and heavy volume set up a clear mean-reversion test and defined levels to watch on XETRA in Germany.
MDG1.DE stock: price action and liquidity
Medigene AG (MDG1.DE) opened €0.16 and fell to a day low of €0.08, closing the pre-market quote at €0.1335. Volume spiked to 189,470, versus an average of 43,152, giving a relative volume of 4.39 and making intraday movement tradable. Higher intraday volume increases the chance of an oversold bounce, but also raises execution risk. Traders should use tight sizing and watch bid-ask spreads on XETRA in EUR.
MDG1.DE stock: fundamentals and valuation
Medigene reports EPS -1.21 and a negative PE near -0.11, reflecting losses. Balance sheet metrics show cash per share €1.36 and book value per share €1.72, while market cap stands at €1,967,470 and shares outstanding are 14,737,600. Price-to-book and price-to-sales ratios appear cheap, but R&D spending and recurring losses mean valuation reflects severe execution risk for the biotechnology sector in Germany.
MDG1.DE stock: technicals and oversold bounce setup
Price sits well below the 50-day (€1.41) and 200-day (€1.66) averages, a textbook oversold gap. The stock is down -91.91% over three months, making short-term mean reversion possible if buying volume follows. Key intraday levels: support near €0.08 and initial resistance at €0.16 then €0.25. Use tight stops below the day low for this high-volatility trade.
MDG1.DE stock: Meyka AI grade and analyst context
Meyka AI rates MDG1.DE with a score of 57.97 out of 100 (Grade C+, Suggestion: HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. The company rating on broader screens shows weak profitability metrics, but cash per share and current ratio provide short-term solvency buffers. These grades are informational and not investment advice.
MDG1.DE stock: risks, catalysts and sector context
Primary risks are continued dilution, trial setbacks, and low liquidity with a small market cap. Medigene’s partnerships, including work with 2seventy bio, remain catalysts if clinical updates arrive. Biotech sector performance in Germany is mixed; drug development timelines can rapidly change the outlook. See peer comparison data for context source and source.
MDG1.DE stock: price targets and a trading plan
For an oversold-bounce approach, consider a conservative short-term target €0.25 and a swing target €0.40. Set a stop-loss near the intraday low of €0.07–€0.09 and scale size to account for high volatility. Meyka AI’s forecast model projects these recovery scenarios versus the current price €0.1335. Forecasts are model-based projections and not guarantees.
Final Thoughts
MDG1.DE stock traded at €0.1335 pre-market on 16 Jan 2026 after a heavy -27.64% move and a volume surge to 189,470 shares. That combination creates a classic oversold-bounce setup for short-term traders, but the fundamental picture remains weak: trailing EPS is -1.21, the PE is negative, and the company carries biotech execution risk. Meyka AI’s rules-based grade is C+ (57.97), reflecting the mix of cheap valuation ratios and operational weakness. For traders, a conservative bounce target of €0.25 implies an upside of 87.27% from €0.1335; a more aggressive swing to €0.40 implies 199.63% upside. Use tight stops and small position sizes given liquidity and dilution risk. Meyka AI, an AI-powered market analysis platform, flags this setup as high reward but high risk. Forecasts are model-based projections and not guarantees.
FAQs
What caused the MDG1.DE stock drop pre-market on 16 Jan 2026?
The pre-market drop to €0.1335 was driven by heavy selling and high volume. No single public catalyst was posted; liquidity and technical selling amplified declines. Clinical or funding news could follow, so watch official releases.
Is MDG1.DE stock a buy on this oversold bounce?
An oversold bounce can offer short-term gains, but fundamentals are weak. Use small sizes, short stops, and targets like €0.25. This is a speculative trade, not a long-term buy recommendation.
What are key levels to watch for MDG1.DE stock today?
Watch intraday support near €0.08, initial resistance at €0.16, and secondary resistance around €0.25. Volume confirmation above average improves bounce odds.
How does Meyka AI rate MDG1.DE stock?
Meyka AI rates MDG1.DE with a score of 57.97/100 (Grade C+, Suggestion: HOLD). The grade factors sector, growth, metrics, and consensus and is informational only.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
